Hironori Fukuda1, Tsunenori Kondo2, Toshio Takagi1, Jumpei Iizuka1, Yoji Nagashima3, Kazunari Tanabe1. 1. Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-Ku, Tokyo, Japan. 2. Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-Ku, Tokyo, Japan. tkondo@kc.twmu.ac.jp. 3. Department of Surgical Pathology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-Ku, Tokyo, Japan.
Abstract
BACKGROUND: The clinical benefit of targeted molecular therapy (TMT) for an inferior vena cava (IVC) tumor thrombus associated with renal cell carcinoma (RCC) is unclear. The aim of the present study was to assess the change in IVC thrombus height during TMT and to identify the factors associated with the effect of TMT on an IVC thrombus in RCC patients. METHODS: The present study retrospectively analyzed 21 patients with an IVC thrombus who were treated with TMT at our hospital. Thrombus height and level before and after TMT were assessed using CT or MRI. Furthermore, we examined the factors associated with the effect of TMT on the IVC thrombus. RESULTS: The tumor thrombus level before TMT was I in 2 patients (10%), II in 10 (47%), III in 4 (19%), and IV in 5 (24%). Following TMT, the tumor thrombus height decreased in 16 patients (76%), and the mean decrease was 17 mm. The tumor thrombus height increased in 5 patients (24%), and the mean increase was 30 mm. The tumor thrombus level decreased in 4 patients (19%), remained stable in 15 patients (71%), and increased in 2 patients (10%). We found that the clinical nodal stage (p = 0.025) was significantly associated with and the serum neutrophil count (p = 0.067) tended to be associated with the reduction in the IVC thrombus. CONCLUSION: The clinical benefit of TMT for an IVC thrombus associated with RCC is limited.
BACKGROUND: The clinical benefit of targeted molecular therapy (TMT) for an inferior vena cava (IVC) tumor thrombus associated with renal cell carcinoma (RCC) is unclear. The aim of the present study was to assess the change in IVC thrombus height during TMT and to identify the factors associated with the effect of TMT on an IVC thrombus in RCCpatients. METHODS: The present study retrospectively analyzed 21 patients with an IVC thrombus who were treated with TMT at our hospital. Thrombus height and level before and after TMT were assessed using CT or MRI. Furthermore, we examined the factors associated with the effect of TMT on the IVC thrombus. RESULTS: The tumor thrombus level before TMT was I in 2 patients (10%), II in 10 (47%), III in 4 (19%), and IV in 5 (24%). Following TMT, the tumor thrombus height decreased in 16 patients (76%), and the mean decrease was 17 mm. The tumor thrombus height increased in 5 patients (24%), and the mean increase was 30 mm. The tumor thrombus level decreased in 4 patients (19%), remained stable in 15 patients (71%), and increased in 2 patients (10%). We found that the clinical nodal stage (p = 0.025) was significantly associated with and the serum neutrophil count (p = 0.067) tended to be associated with the reduction in the IVC thrombus. CONCLUSION: The clinical benefit of TMT for an IVC thrombus associated with RCC is limited.
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Nicholas G Cost; Scott E Delacroix; Joshua P Sleeper; Paul J Smith; Ramy F Youssef; Brian F Chapin; Jose A Karam; Stephen Culp; E Jason Abel; James Brugarolas; Ganesh V Raj; Arthur I Sagalowsky; Christopher G Wood; Vitaly Margulis Journal: Eur Urol Date: 2011-02-23 Impact factor: 20.096
Authors: Juan I Martínez-Salamanca; William C Huang; Isabel Millán; Roberto Bertini; Fernando J Bianco; Joaquin A Carballido; Gaetano Ciancio; Carlos Hernández; Felipe Herranz; Axel Haferkamp; Markus Hohenfellner; Brian Hu; Theresa Koppie; Claudio Martínez-Ballesteros; Francesco Montorsi; Joan Palou; J Edson Pontes; Paul Russo; Carlo Terrone; Humberto Villavicencio; Alessandro Volpe; John A Libertino Journal: Eur Urol Date: 2010-10-13 Impact factor: 20.096
Authors: Erica H Lambert; Phillip M Pierorazio; Ahmad Shabsigh; Carl A Olsson; Mitchell C Benson; James M McKiernan Journal: Urology Date: 2007-06 Impact factor: 2.649
Authors: Paul Sweeney; Christopher G Wood; Louis L Pisters; Joel W Slaton; Ara Vaporciyan; Mark Munsell; Scott Carpenter; Joe Putnam; Stephen G Swisher; Garret Walsh; David Swanson; Colin P N Dinney Journal: Urol Oncol Date: 2003 Sep-Oct Impact factor: 3.498
Authors: Grant D Stewart; Sarah J Welsh; Stephan Ursprung; Ferdia A Gallagher; James O Jones; Jacqui Shields; Christopher G Smith; Thomas J Mitchell; Anne Y Warren; Axel Bex; Ekaterini Boleti; Jade Carruthers; Tim Eisen; Kate Fife; Abdel Hamid; Alexander Laird; Steve Leung; Jahangeer Malik; Iosif A Mendichovszky; Faiz Mumtaz; Grenville Oades; Andrew N Priest; Antony C P Riddick; Balaji Venugopal; Michelle Welsh; Kathleen Riddle; Lisa E M Hopcroft; Robert J Jones Journal: Br J Cancer Date: 2022-06-23 Impact factor: 9.075